Diagnostics Channel NavClinical Channel NavInformatics Channel NavCancer Channel NavRegister Nav
MMTC15_Header  
MMTC M Header 

Cambridge Healthtech Institute’s Second Annual

Digital Pathology

Transforming Medicine in a Digital World

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA

 

Day 1 | Day 2 | Day 3 | Download Brochure 

Tuesday, February 11

7:00 am Registration and Morning Coffee

8:00 Plenary Keynote Session (Click Here For More Details)  

 

 

 

MULTIPLEXING 

10:25am Chairperson’s Remarks

Kenneth J. Bloom, M.D., CMO, Clarient, Inc.

10:30 Overview of Multiplexing and Novel Microscopy Platforms: So Many Biomarkers, So Little Tissue…

Richard Levenson, M.D., Professor and Vice Chair, Strategic Technologies, Pathology & Laboratory Medicine, University of California, Davis Medical Center

Pathology is evolving to accommodate an explosion of molecular markers being used for diagnostic, prognostic, and therapy-guidance purposes. At the same time, minimally invasive procedures are generating ever smaller tissue samples to be analyzed. Fortunately, new multiplexing reagents, improved microscope optics and sensors, and advanced software tools can help.

11:00 Predicting Response to Targeted Therapy in Solid Tumors Using Multivariate Indices based on Protein Biomarker Expression

Vladimir Knezevic, M.D., Senior Vice President, Research & Development, 20/20 GeneSystems, Inc.

Companion diagnostics are expected to guide future treatment decisions by identifying the patients most likely to benefit from a particular (often highly priced) cancer therapeutic. Also, by ruling out therapies that are not likely to be effective, this approach could save unnecessary costs and improve standard of care. 20/20 GeneSystems, Inc. is utilizing unique layered immunohistochemistry technology to develop assays for analysis of multiple protein biomarkers in solid tumors.

11:30 Multiplexing in a CLIA Environment

Kenneth J. Bloom, M.D., CMO, Clarient, Inc.

The size of biopsy samples is getting smaller and smaller the number of actionable therapeutic targets is increasing.  There are many practical aspects to consider when implementing multiplexing procedures and there are even more considerations when implementing a complex test  in a CLIA environment.  I will review our experience with implementing a 9-plex  immunostain in our clinical lab and discuss issues likely to be encountered when expanding the IHC panels to include DNA and RNA probes.

12:00 pm Sponsored Presentations (Opportunities Available)


12:30 Session Break


12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own


1:40 Refreshment Break in the Exhibit Hall with Poster Viewing
 

 

QUANTITATIVE BIOMARKERS 

2:15pm Chairperson’s Remarks

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University

2:20 The Quest for a Universal Fixative: Measuring Fixative-induced Morphologic and Antigenic Variation

Alexander “Sandy” Borowsky, M.D., Center for Comparative Medicine, University of California, Davis

Quantitative Image Analysis (QIA) for morphometric parameters and immunohistochemistry of breast cancer antigens was used to evaluate the technical reproducibility, biological variability, and intratumoral heterogeneity in animal tumor models and compared to human clinical samples in several ways. This talk will review the findings on the technical reproducibility and biological heterogeneity as well as the results of fixatives in both morphometric and immunohistochemical parameters.

2:50 New Methods for Multi-Parameter Quantitative in situ Biomarker Assessment: Nucleic Acids vs. Proteins

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University

While in situ protein and DNA measurements (quantitative or semi-quantitatively) have been done for years, in situ hybridization (ISH) for RNA has historically been challenging. On the other hand, the types and functions for RNA, now including microRNA and long non-coding (linc) RNA have expanded dramatically over the last few years. Here we describe methods for quantitative nucleic acid measurement and discuss comparisons between RNA measurements by RT-PCR vs. quantitative ISH.

3:20 Mass Tags and IHC—A New Frontier for 100 Parameters and Above

Garry P. Nolan, Ph.D., Rachford and Carlota A. Harris Professor, Microbiology & Immunology, Stanford School of Medicine; Director, NHLBI Proteomics Center for Systems Immunology; Baxter Laboratory for Stem Cell Biology, Center for Clinical Science Research

Multiparameter single cell analysis (MPSCA) for histological and non-adherent cells has been a critical mainstay of clinical diagnostic procedures for decades. Recent innovations using mass spectrometry tags for single cell analysis in conjunction with inductively coupled mass spectrometry and secondary ion mass spectrometry is radically altering analysis frontiers. I will discuss such innovations and informatics approaches to data analysis and representation of results from clinical samples in such high dimensionality arenas.

3:50 pm Quantitative Image Analysis of Biomarkers in Breast Cancer: From Bench Side to Bed Side

Marilyn Bui, M.D., Ph.D., Director, Analytic Microscopy Core, Director, Cytopathology Fellowship Program, Associate Member & Professor, Anatomic Pathology, Sarcoma and Experimental Therapeutics, Moffitt Cancer Center; Oncological Sciences, Cell Biology, Pathology, Morsani College of Medicine, University of South Florida

This presentation will discuss the application of quantitative image analysis in the translational research of breast cancer, as well as the implementation of the FDA-approved breast algorithms into clinical practice.

4:20 Valentine’s Day Celebration in the Exhibit Hall with Poster Viewing

 

5:20 Breakout Discussions in the Exhibit Hall 

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.

The Value Proposition of Digital Pathology 

Anil Parwani, M.D., Ph.D., Director, Pathology Informatics, Pathology, University of Pittsburgh Medical Center 

  • Significant advances in technology allow us to rapidly digitize large number of pathology slides
  • An important question is what is the value proposition of this to the pathology laboratory
  • Is the cost prohibitive to adopt the technology?
  • Can we use the technology for some applications where the justification for the added cost
  • What are some challenges and barriers for adoption of this technology

Use of Whole Slide Imaging for Primary Diagnosis in Canada 

Andrew J. Evans, M.D., Ph.D., FRCPC, Staff Pathologist & Associate  Professor, University Health Network, Laboratory Medicine Program 

  • Required due diligence concerning medical malpractice/liability coverage
  • Health Canada’s classification and approval of specific WSI platforms for routine diagnostic use
  • Health Canada and CE mark approval for WSI versus the FDA process
  • Peer-reviewed literature showing non-inferiority of WSI relative to the light microscope
  • Importance of WSI-LIS integration to support larger volume digital reporting
 

6:30 Close of Day

MMTC Digital Path gif 

Day 1 | Day 2 | Day 3 | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 



2014 Premier Sponsors:

 Elsevier   

 

NanoString 

 

Quanterix 

 

RemedyMD 

 

Singulex 

 

Thomson Reuters